21 Nov 2026
NEWS · CONTEXT · PERSPECTIVE
English

News in perspective.
Context. Clarity. Sources.

Hot topics, news and trends shaping the world

Early pancreatic cancer study reports tumour responses in 61-patient group

Revolution Medicines reported confirmed responses in 60.7% of participants given daraxonrasib with chemotherapy. A larger comparative trial is ongoing.

Editorial policy

Illustrative photograph of patient care via The Guardian, supplied in News Scout. It does not show a participant in the study.
Illustrative photograph of patient care by Jeff Moore/PA, via The Guardian, supplied in News Scout. It does not show a participant in the study. Editorial collage and drawing made with AI assistance.

In an early-stage study of 61 people with previously untreated metastatic pancreatic adenocarcinoma, 60.7% had a confirmed tumour response after receiving daraxonrasib with two chemotherapy drugs, Revolution Medicines reported. Complete responses were recorded in 8.2% of participants. A complete response describes what was measurable on scans at assessment and does not establish that the cancer was cured.

Participants in that group all received the combination, so the results cannot show what daraxonrasib adds to chemotherapy alone. The sponsor reported estimated survival of 76.6% at 12 months and a median follow-up of 18.3 months. The data were presented at the ENA meeting in Barcelona on 20 November.

The U.S. Food and Drug Administration approved daraxonrasib in August for adults with metastatic pancreatic adenocarcinoma who had previously received systemic treatment or could not receive multiagent systemic treatment. The study reported this week concerns a different question: using the combination as initial treatment. The phase 3 RASolute 303 trial is testing daraxonrasib with and without chemotherapy against chemotherapy alone in that setting.

Sources

  1. Early pancreatic cancer study reports tumour responses in 61-patient group — Revolution Medicines
  2. FDA approval and indication — U.S. Food and Drug Administration
Assigned writer
Jack ThompsonCredit pending confirmation
Assigned reviewer
Sophie TaylorReview pending

Published